• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The development of polycythemia vera after phlebotomy treatment for hereditary haemochromatosis.

作者信息

van Bommel Erik Jm, Kelder Denise, Hoeks Marlijn Pa, Herbers Alexandra He

机构信息

Department of Internal Medicine/Haematology Jeroen Bosch Hospital 's-Hertogenbosch The Netherlands.

Department of haematology Radboud University Medical Center Nijmegen The Netherlands.

出版信息

EJHaem. 2021 May 21;2(3):537-538. doi: 10.1002/jha2.222. eCollection 2021 Aug.

DOI:10.1002/jha2.222
PMID:35844679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176116/
Abstract
摘要

相似文献

1
The development of polycythemia vera after phlebotomy treatment for hereditary haemochromatosis.遗传性血色素沉着症放血治疗后真性红细胞增多症的发展。
EJHaem. 2021 May 21;2(3):537-538. doi: 10.1002/jha2.222. eCollection 2021 Aug.
2
The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.治疗性红细胞单采术与放血疗法的疗效比较：一种预测遗传性血色素沉着症、真性红细胞增多症和继发性红细胞增多症反应的数学工具。
J Clin Apher. 2014 Jun;29(3):133-8. doi: 10.1002/jca.21303. Epub 2013 Oct 15.
3
Interventions for hereditary haemochromatosis: an attempted network meta-analysis.遗传性血色素沉着症的干预措施：一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 8;3(3):CD011647. doi: 10.1002/14651858.CD011647.pub2.
4
The efficiency of therapeutic erythrocytapheresis compared to phlebotomy in relation to blood volume and delta-hematocrit: an evaluation in hereditary hemochromatosis polycythemia vera and secondary erythrocytosis.与放血疗法相比，治疗性红细胞单采术在血容量和红细胞压积变化方面的效率：对遗传性血色素沉着症、真性红细胞增多症和继发性红细胞增多症的评估
Transfus Apher Sci. 2013 Apr;48(2):187. doi: 10.1016/j.transci.2013.02.030. Epub 2013 Mar 13.
5
Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.真性红细胞增多症中的铁调素类似物：解决缺铁和红细胞增多之间的矛盾。
Curr Opin Hematol. 2023 Mar 1;30(2):45-52. doi: 10.1097/MOH.0000000000000747. Epub 2022 Dec 29.
6
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.放血疗法方案强度与真性红细胞增多症血栓形成风险无相关性：来自真性红细胞增多症低剂量阿司匹林欧洲协作组及真性红细胞增多症细胞减灭治疗临床试验的证据。
Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2.
7
Polycythemia vera: a retrospective and reprise.真性红细胞增多症：回顾与重述
J Lab Clin Med. 1997 Oct;130(4):365-73. doi: 10.1016/s0022-2143(97)90035-4.
8
5-azacitidine reversing "spent" phase polycythemia vera back to proliferative phase and need for phlebotomy.5-氮杂胞苷可将“耗竭”期真性红细胞增多症逆转至增殖期并减少放血需求。
J Oncol Pharm Pract. 2020 Jul;26(5):1285-1288. doi: 10.1177/1078155220901769. Epub 2020 Feb 13.
9
Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.红细胞单采术与全血采血术治疗遗传性血色素沉着症的比较。
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s84-9. doi: 10.2450/2013.0128-13. Epub 2013 Oct 23.
10
Polycythemia vera and the Jak2(V617F) mutation in a case of hereditary spherocytosis.遗传性球形红细胞增多症病例中的真性红细胞增多症和 Jak2(V617F)突变。
Am J Med Sci. 2013 Oct;346(4):328-30. doi: 10.1097/MAJ.0b013e31828c9df6.

本文引用的文献

1
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
2
HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease.HFE C282Y突变作为一种影响慢性骨髓增殖性疾病易感性的基因修饰因子。
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):929-34. doi: 10.1158/1055-9965.EPI-08-0359. Epub 2009 Mar 3.
3
JAK2 Mutations are present in all cases of polycythemia vera.真性红细胞增多症的所有病例中均存在JAK2突变。
Leukemia. 2008 Jun;22(6):1289. doi: 10.1038/sj.leu.2405047. Epub 2007 Dec 13.
4
Analysis of hemochromatosis gene mutations in 52 consecutive patients with polycythemia vera.对52例连续性真性红细胞增多症患者的血色素沉着症基因突变分析。
Hematology. 2004 Oct-Dec;9(5-6):413-4. doi: 10.1080/10245330400001934.
5
Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders.
Haematologica. 2002 Feb;87(2):131-5.
6
Epidemiological data in polycythaemia vera: a study of 842 cases.真性红细胞增多症的流行病学数据：一项842例病例的研究。
Hematol Cell Ther. 1998 Aug;40(4):159-65.
7
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.一种新的MHC I类样基因在遗传性血色素沉着症患者中发生突变。
Nat Genet. 1996 Aug;13(4):399-408. doi: 10.1038/ng0896-399.